Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Emergent BioSolutions Inc EBS

Healthcare Biotechnology
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial... see more

Recent & Breaking News (NYSE:EBS)

Emergent BioSolutions Announces $35 Million Option Exercised by the Initial Purchasers of the Company's Convertible Senior Notes

Business Wire January 27, 2014

Emergent BioSolutions Announces Pricing of Offering of $215 Million of 2.875% Convertible Senior Notes

Business Wire January 23, 2014

Emergent BioSolutions Announces Proposed Offering of $200 Million Convertible Senior Notes

Business Wire January 22, 2014

Emergent BioSolutions Announces Preliminary 2013 Financial Results and Provides 2014 Forecast

Business Wire January 13, 2014

Emergent BioSolutions to Acquire Cangene Corporation

Business Wire December 11, 2013

Emergent BioSolutions' Otlertuzumab (TRU-016) Shows Positive Results in Combination with Rituximab in People with CLL

Business Wire December 10, 2013

Emergent BioSolutions Presents Positive Interim Phase 2 Data Evaluating Otlertuzumab (TRU-016) in Combination with Bendamustine in People with Relapsed Chronic Lymphocytic Leukemia

Business Wire December 9, 2013

Emergent BioSolutions to Webcast Presentation at the 32nd Annual J.P. Morgan Healthcare Conference

Business Wire December 2, 2013

Emergent BioSolutions Appoints A.B. Cruz III as Executive Vice President and General Counsel

Business Wire November 26, 2013

Emergent BioSolutions to Webcast Its Participation at the 25th Annual Piper Jaffray Healthcare Conference

Business Wire November 20, 2013

Emergent BioSolutions Announces Acceptance of Otlertuzumab Abstracts for Presentation at 2013 American Society of Hematology Annual Meeting

Business Wire November 7, 2013

Emergent BioSolutions Presents Preclinical Data on ES414, Its Lead Bispecific ADAPTIR Therapeutic for Prostate Cancer

Business Wire November 6, 2013

Emergent BioSolutions Wins 2013 North American Maintenance Excellence Award

Business Wire October 28, 2013

Emergent BioSolutions to Webcast Presentation at Credit Suisse 2013 Healthcare Conference

Business Wire October 15, 2013

Emergent BioSolutions to Release Third Quarter 2013 Financial Results and Conduct a Conference Call on November 7, 2013

Business Wire October 7, 2013

Emergent BioSolutions Appoints Barry Labinger as Executive Vice President of the Company and President of Its Biosciences Division

Business Wire August 16, 2013

Emergent BioSolutions Reports Financial Results for Second Quarter and First Six Months of 2013

Business Wire August 5, 2013

Emergent BioSolutions Closes on Its Acquisition of Healthcare Protective Products Division from Bracco Diagnostics Inc.

Business Wire August 2, 2013

Emergent BioSolutions to Webcast Presentation at Wedbush 2013 Life Sciences Management Access Conference

Business Wire July 24, 2013

General George A. Joulwan Joins Emergent BioSolutions Board of Directors

Business Wire July 18, 2013